Takeda Pharmaceutical Co Ltd/ US8740602052 /
| 9/22/2023 9:59:51 PM | Chg. -0.10 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 15.83USD | -0.63% | 72,577 Turnover: 1.15 mill. |
-Bid Size: - | -Ask Size: - | 46.39 bill.USD | - | - |
Fundamentals
| FY 2022 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 147.14 JPY | -38.88% |
| EPS Diluted: | - JPY | - |
| Revenues per Share: | - JPY | - |
| Book Value per Share: | - JPY | - |
| Cash Flow per Share: | - JPY | - |
| Dividend per Share: | - JPY | - |
| Total | in mill. | |
| Revenues: | 3,569,006.00 JPY | 11.61% |
| Net Income: | 230,059.00 JPY | -38.81% |
| Operating Cash Flow: | 1,123,105.00 JPY | - |
| Cash and Cash Equivalents: | 849,695.00 JPY | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | - | - |
| P/S Ratio: | - | - |
| P/BV ratio: | - | - |
| P/CF Ratio: | - | - |
| PEG: | - | - |
| Earnings Yield: | - | - |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 46.39 bill. USD | 42.1 bill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | - | |
Profitability
| Gross Profit Margin: | 68.99% |
| EBIT Margin: | 12.91% |
| Net Profit Margin: | 6.45% |
| Return on Equity: | 4.05% |
| Return on Assets: | 1.75% |
Financial Strength
| Liquidity I / Cash Ratio: | 39.60% |
| Liquidity II / Quick Ratio: | 72.07% |
| Liquidity III / Current Ratio: | 120.87% |
| Debt / Equity Ratio: | 131.88% |
| Dynam. Debt / Equity Ratio: | 667.35% |
Efficiency
| Employees: | 47,000 |
| Personal Expenses / Employee: | - JPY |
| Revenues / Employee: | 75,936,297.87 JPY |
| Net Income / Employee: | 4,894,872.34 JPY |
| Total Assets / Employee: | 280,383,361.70 JPY |
| * Fiscal Year End: | 3/31/2022 |
| Accounting Standard: | IFRS |
| Currency: | JPY |